Sorafenib Relapase Prophylaxis After HCT With PTBCy Regimen

This is a single-center randomized open-label phase II clinical trial to compare relapse prophylaxis with sorafenib and observation after graft-versus-host disease prophylaxis with post-transplantation bendamustine and cyclophosphamide in high-risk myeloid malignancies. This is an intention to treat study, where randomization is performed at first documentation of CR after engraftment.

NCT Number	NCT06532084
Lead Sponsor	St. Petersburg State Pavlov Medical University
Conditions	Acute Myeloid Leukemia, in Relapse, Myelodysplastic Syndromes, Chronic Myeloid Leukemia, Myeloproliferative Neoplasm
Enrollment	88 participants
Start Date	2024-05-22
Primary Completion	2027-05 (estimated)
Study Completion	2028-05 (estimated)
Updated on ClinicalTrials.gov	2024-08-01